Back to List View Graph View

Cyclophosphamide

Cyclophosphamide is a widely used cytotoxic alkylating agent in oncology and immunology.

Where the papers sit

15 papers from the last 6 months study cyclophosphamide directly · updated from PubMed 14 Nov 2026

Those 15 are all about one subject.

  • Therapeutic Use Across Diseases

    Cyclophosphamide is used across sarcoma, lymphoma, myeloma, glioma, autoimmune disease and transplantation, with efficacy, immune reconstitution and long-term safety as recurring endpoints. Studies compare chemotherapy regimens, antibody- or kinase-based strategies, stem-cell mobilization and B-cell depletion rather than pursuing one treatment question. Toxicities including hepatotoxicity, infection, neurologic effects and second malignancies remain recurrent concerns, while nanoparticle delivery and checkpoint blockade seek to widen benefit. The set supports broad clinical utility but not a single directional trend.

    15 papers

PARADIGM SHIFT

Cyclophosphamide can function as an antitumor immune-priming agent rather than only as cytotoxic or lymphodepleting chemotherapy

The glioma study using D8/RI-VAP-modified chitosan nanoparticles and the melanoma mouse study combining cyclophosphamide with immune checkpoint blockade assumed or employed cyclophosphamide within a chemotherapy-centered framework, but both found that it could actively reorganize antitumor immunity: nanoparticle-delivered drug induced immunogenic cell death, dendritic-cell maturation, and recruitment of CD4+ and CD8+ T cells in glioma, while cyclophosphamide given before checkpoint blockade expanded tumor-reactive effector T-cell clones and delayed melanoma progression. Together, these findings shift cyclophosphamide from being regarded chiefly as a tumor-killing or immune-depleting component to a treatment that can prime and redirect adaptive antitumor responses, making delivery and sequencing with immunotherapy central therapeutic considerations 42341589Jun 42329854Jun.

cyclophosphamide chemical structure

Papers

The 15 papers from the last 6 months that study cyclophosphamide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Therapeutic Use Across Diseases (15)
  1. Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing's sarcoma treatment: A network meta-analysis. Medicine · 13 Nov 2026 PMID 43024289
  2. Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience. Cancer · 27 Oct 2026 PMID 42944591
  3. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. RMD open · 25 Sept 2026 PMID 42791028
  4. Reversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 11 Sept 2026 PMID 42726292
  5. Longitudinal Immunophenotypic Changes in Refractory Lupus Nephritis After B-cell Depletion: A 25-year Case Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665415
  6. Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Journal of comparative effectiveness research · 21 Aug 2026 PMID 42626928
  7. Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial. Blood advances · 14 Jul 2026 PMID 42448319
  8. Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 10 Jul 2026 PMID 42431019
  9. Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study. Cancer · 2 Jul 2026 PMID 42390889
  10. Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
  11. Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
  12. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  13. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
  14. Ameliorating effects of Coenzyme Q10 and its nanosuspension against cyclophosphamide-induced hepatoxicity in rats. Biochemical and biophysical research communications · 13 Jun 2026 PMID 42288037
  15. Longitudinal changes in brain volume, cognitive function, and seizure outcomes in cryptogenic new-onset refractory status epilepticus. Journal of the neurological sciences · 25 May 2026 PMID 42184585

By study type

Clinical trials (2)
  1. Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial. Blood advances · 14 Jul 2026 PMID 42448319
  2. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia · 18 Jun 2026 PMID 42315418
Observational studies and case reports (7)
  1. Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience. Cancer · 27 Oct 2026 PMID 42944591
  2. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. RMD open · 25 Sept 2026 PMID 42791028
  3. Reversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 11 Sept 2026 PMID 42726292
  4. Longitudinal Immunophenotypic Changes in Refractory Lupus Nephritis After B-cell Depletion: A 25-year Case Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665415
  5. Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 10 Jul 2026 PMID 42431019
  6. Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
  7. Longitudinal changes in brain volume, cognitive function, and seizure outcomes in cryptogenic new-onset refractory status epilepticus. Journal of the neurological sciences · 25 May 2026 PMID 42184585
Human data, design not indexed (3)
  1. Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing's sarcoma treatment: A network meta-analysis. Medicine · 13 Nov 2026 PMID 43024289
  2. Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Journal of comparative effectiveness research · 21 Aug 2026 PMID 42626928
  3. Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study. Cancer · 2 Jul 2026 PMID 42390889
Preclinical: animal, cell and lab studies (3)
  1. Repurposing of cyclophosphamide as a chemo‑immunotherapy agent in glioma using D8/RI‑VAP modified-chitosan nanoparticles. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jun 2026 PMID 42341589
  2. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  3. Ameliorating effects of Coenzyme Q10 and its nanosuspension against cyclophosphamide-induced hepatoxicity in rats. Biochemical and biophysical research communications · 13 Jun 2026 PMID 42288037